Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression.

Pušnik J, Eller MA, Tassaneetrithep B, Schultz BT, Eller LA, Nitayaphan S, Kosgei J, Maganga L, Kibuuka H, Alter G, Michael NL, Robb ML, Streeck H.

J Virol. 2019 Jun 28;93(14). pii: e00377-19. doi: 10.1128/JVI.00377-19. Print 2019 Jul 15.

PMID:
31043532
2.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
3.

The CD4-CD8- MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8+ MAIT cell pool.

Dias J, Boulouis C, Gorin JB, van den Biggelaar RHGA, Lal KG, Gibbs A, Loh L, Gulam MY, Sia WR, Bari S, Hwang WYK, Nixon DF, Nguyen S, Betts MR, Buggert M, Eller MA, Broliden K, Tjernlund A, Sandberg JK, Leeansyah E.

Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):E11513-E11522. doi: 10.1073/pnas.1812273115. Epub 2018 Nov 15.

4.

Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques.

Tokarev A, Creegan M, Eller MA, Roederer M, Bolton DL.

J Vis Exp. 2018 Sep 25;(139). doi: 10.3791/57776.

PMID:
30320741
5.

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.

Pissani F, Schulte B, Eller MA, Schultz BT, Ratto-Kim S, Marovich M, Thongcharoen P, Sriplienchan S, Rerks-Ngarm S, Pitisuttithum P, Esser S, Alter G, Robb ML, Kim JH, Michael NL, Streeck H.

J Virol. 2018 Nov 12;92(23). pii: e01143-18. doi: 10.1128/JVI.01143-18. Print 2018 Dec 1.

6.

Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans.

Letizia A, Eller MA, Polyak C, Eller LA, Creegan M, Dawson P, Bryant C, D K, Crowell TA, Lombardi K, Rono E, Robb ML, Michael NL, Maswai J, Ake JA.

J Infect Dis. 2019 Jan 7;219(2):284-294. doi: 10.1093/infdis/jiy509.

PMID:
30165548
7.

A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity.

Alrubayyi A, Schuetz A, Lal KG, Jongrakthaitae S, Paolino KM, Ake JA, Robb ML, de Souza MS, Michael NL, Paquin-Proulx D, Eller MA.

J Immunol Methods. 2018 Nov;462:74-82. doi: 10.1016/j.jim.2018.08.012. Epub 2018 Aug 24.

8.

Evolution of HIV-1 within untreated individuals and at the population scale in Uganda.

Raghwani J, Redd AD, Longosz AF, Wu CH, Serwadda D, Martens C, Kagaayi J, Sewankambo N, Porcella SF, Grabowski MK, Quinn TC, Eller MA, Eller LA, Wabwire-Mangen F, Robb ML, Fraser C, Lythgoe KA.

PLoS Pathog. 2018 Jul 27;14(7):e1007167. doi: 10.1371/journal.ppat.1007167. eCollection 2018 Jul.

9.

Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans.

Rao M, Onkar S, Peachman KK, White Y, Trinh HV, Jobe O, Zhou Y, Dawson P, Eller MA, Matyas GR, Alving CR.

J Infect Dis. 2018 Oct 5;218(10):1541-1550. doi: 10.1093/infdis/jiy348.

PMID:
29893872
10.

Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size.

Teigler JE, Leyre L, Chomont N, Slike B, Jian N, Eller MA, Phanuphak N, Kroon E, Pinyakorn S, Eller LA, Robb ML, Ananworanich J, Michael NL, Streeck H, Krebs SJ; RV254/RV217 study groups.

JCI Insight. 2018 May 17;3(10). pii: 98420. doi: 10.1172/jci.insight.98420. eCollection 2018 May 17.

11.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group .

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

12.

Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.

Buggert M, Nguyen S, McLane LM, Steblyanko M, Anikeeva N, Paquin-Proulx D, Del Rio Estrada PM, Ablanedo-Terrazas Y, Noyan K, Reuter MA, Demers K, Sandberg JK, Eller MA, Streeck H, Jansson M, Nowak P, Sönnerborg A, Canaday DH, Naji A, Wherry EJ, Robb ML, Deeks SG, Reyes-Teran G, Sykulev Y, Karlsson AC, Betts MR.

PLoS Pathog. 2018 Apr 13;14(4):e1006973. doi: 10.1371/journal.ppat.1006973. eCollection 2018 Apr.

13.

Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination.

Costanzo MC, Kim D, Creegan M, Lal KG, Ake JA, Currier JR, Streeck H, Robb ML, Michael NL, Bolton DL, Steers NJ, Eller MA.

Nat Commun. 2018 Mar 23;9(1):1212. doi: 10.1038/s41467-018-03618-w.

14.

OMIP-046: Characterization of invariant T cell subset activation in humans.

Lal KG, Leeansyah E, Sandberg JK, Eller MA.

Cytometry A. 2018 May;93(5):499-503. doi: 10.1002/cyto.a.23357. Epub 2018 Mar 13. No abstract available.

15.

Turning Data Into Information: Opportunities to Advance Rehabilitation Quality, Research, and Policy.

Bettger JP, Nguyen VQC, Thomas JG, Guerrier T, Yang Q, Hirsch MA, Pugh T, Harris G, Eller MA, Pereira C, Hamm D, Rinehardt EA, Shall M, Niemeier JP.

Arch Phys Med Rehabil. 2018 Jun;99(6):1226-1231. doi: 10.1016/j.apmr.2017.12.029. Epub 2018 Jan 31.

16.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, Robb ML.

J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456.

17.

Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection.

Kijak GH, Sanders-Buell E, Chenine AL, Eller MA, Goonetilleke N, Thomas R, Leviyang S, Harbolick EA, Bose M, Pham P, Oropeza C, Poltavee K, O'Sullivan AM, Billings E, Merbah M, Costanzo MC, Warren JA, Slike B, Li H, Peachman KK, Fischer W, Gao F, Cicala C, Arthos J, Eller LA, O'Connell RJ, Sinei S, Maganga L, Kibuuka H, Nitayaphan S, Rao M, Marovich MA, Krebs SJ, Rolland M, Korber BT, Shaw GM, Michael NL, Robb ML, Tovanabutra S, Kim JH.

PLoS Pathog. 2017 Sep 14;13(9):e1006620. doi: 10.1371/journal.ppat.1006620. eCollection 2017 Sep.

18.

Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.

Teigler JE, Zelinskyy G, Eller MA, Bolton DL, Marovich M, Gordon AD, Alrubayyi A, Alter G, Robb ML, Martin JN, Deeks SG, Michael NL, Dittmer U, Streeck H.

J Virol. 2017 Nov 14;91(23). pii: e01263-17. doi: 10.1128/JVI.01263-17. Print 2017 Dec 1.

19.

Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection.

Kijak GH, Sanders-Buell E, Chenine AL, Eller MA, Goonetilleke N, Thomas R, Leviyang S, Harbolick EA, Bose M, Pham P, Oropeza C, Poltavee K, O'Sullivan AM, Billings E, Merbah M, Costanzo MC, Warren JA, Slike B, Li H, Peachman KK, Fischer W, Gao F, Cicala C, Arthos J, Eller LA, O'Connell RJ, Sinei S, Maganga L, Kibuuka H, Nitayaphan S, Rao M, Marovich MA, Krebs SJ, Rolland M, Korber BT, Shaw GM, Michael NL, Robb ML, Tovanabutra S, Kim JH.

PLoS Pathog. 2017 Jul 31;13(7):e1006510. doi: 10.1371/journal.ppat.1006510. eCollection 2017 Jul. Erratum in: PLoS Pathog. 2017 Sep 14;13(9):e1006620.

20.

Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers.

Buranapraditkun S, Pissani F, Teigler JE, Schultz BT, Alter G, Marovich M, Robb ML, Eller MA, Martin J, Deeks S, Michael NL, Streeck H.

J Virol. 2017 Jun 26;91(14). pii: e00497-17. doi: 10.1128/JVI.00497-17. Print 2017 Jul 15.

21.

T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Knox JJ, Buggert M, Kardava L, Seaton KE, Eller MA, Canaday DH, Robb ML, Ostrowski MA, Deeks SG, Slifka MK, Tomaras GD, Moir S, Moody MA, Betts MR.

JCI Insight. 2017 Apr 20;2(8). pii: 92943. doi: 10.1172/jci.insight.92943. eCollection 2017 Apr 20.

22.

Ontogeny of CD4+ T Lymphocytes With Phenotypic Susceptibility to HIV-1 During Exclusive and Nonexclusive Breastfeeding in HIV-1-Exposed Ugandan Infants.

McFarland EJ, Powell TM, Onyango-Makumbi C, Zhang W, Melander K, Naluyima P, Okurut S, Eller MA, Fowler MG, Janoff EN.

J Infect Dis. 2017 Feb 1;215(3):368-377. doi: 10.1093/infdis/jiw553.

23.

A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda.

Blanquart F, Grabowski MK, Herbeck J, Nalugoda F, Serwadda D, Eller MA, Robb ML, Gray R, Kigozi G, Laeyendecker O, Lythgoe KA, Nakigozi G, Quinn TC, Reynolds SJ, Wawer MJ, Fraser C.

Elife. 2016 Nov 5;5. pii: e20492. doi: 10.7554/eLife.20492.

24.

Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection.

Demers KR, Makedonas G, Buggert M, Eller MA, Ratcliffe SJ, Goonetilleke N, Li CK, Eller LA, Rono K, Maganga L, Nitayaphan S, Kibuuka H, Routy JP, Slifka MK, Haynes BF, McMichael AJ, Bernard NF, Robb ML, Betts MR.

PLoS Pathog. 2016 Aug 3;12(8):e1005805. doi: 10.1371/journal.ppat.1005805. eCollection 2016 Aug.

25.

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand.

Robb ML, Eller LA, Kibuuka H, Rono K, Maganga L, Nitayaphan S, Kroon E, Sawe FK, Sinei S, Sriplienchan S, Jagodzinski LL, Malia J, Manak M, de Souza MS, Tovanabutra S, Sanders-Buell E, Rolland M, Dorsey-Spitz J, Eller MA, Milazzo M, Li Q, Lewandowski A, Wu H, Swann E, O'Connell RJ, Peel S, Dawson P, Kim JH, Michael NL; RV 217 Study Team.

N Engl J Med. 2016 Jun 2;374(22):2120-30. doi: 10.1056/NEJMoa1508952. Epub 2016 May 18.

26.

Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection.

Eller MA, Goonetilleke N, Tassaneetrithep B, Eller LA, Costanzo MC, Johnson S, Betts MR, Krebs SJ, Slike BM, Nitayaphan S, Rono K, Tovanabutra S, Maganga L, Kibuuka H, Jagodzinski L, Peel S, Rolland M, Marovich MA, Kim JH, Michael NL, Robb ML, Streeck H.

J Virol. 2016 Mar 28;90(8):4005-4016. doi: 10.1128/JVI.02785-15. Print 2016 Apr.

27.

Circulating HIV-Specific Interleukin-21(+)CD4(+) T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions.

Schultz BT, Teigler JE, Pissani F, Oster AF, Kranias G, Alter G, Marovich M, Eller MA, Dittmer U, Robb ML, Kim JH, Michael NL, Bolton D, Streeck H.

Immunity. 2016 Jan 19;44(1):167-178. doi: 10.1016/j.immuni.2015.12.011. Epub 2016 Jan 12.

28.

Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations.

Naluyima P, Eller LA, Ouma BJ, Kyabaggu D, Kataaha P, Guwatudde D, Kibuuka H, Wabwire-Mangen F, Robb ML, Michael NL, de Souza MS, Sandberg JK, Eller MA.

PLoS One. 2016 Jan 5;11(1):e0146196. doi: 10.1371/journal.pone.0146196. eCollection 2016.

29.

Brief Report: Differential Associations of Interleukin 6 and Intestinal Fatty Acid-Binding Protein With Progressive Untreated HIV-1 Infection in Rakai, Uganda.

Olwenyi OA, Naluyima P, Cham F, Quinn TC, Serwadda D, Sewankambo NK, Gray RH, Sandberg JK, Michael NL, Wabwire-Mangen F, Robb ML, Eller MA.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):15-20. doi: 10.1097/QAI.0000000000000915.

30.

OMIP-027: Functional analysis of human natural killer cells.

Costanzo MC, Creegan M, Lal KG, Eller MA.

Cytometry A. 2015 Sep;87(9):803-5. doi: 10.1002/cyto.a.22719. Epub 2015 Jul 17. No abstract available.

31.

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study.

Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, Eller MA, Eller LA, Michael NL, Honko AN, Olinger GG Jr, Schoepp RJ, Hepburn MJ, Hensley LE, Robb ML.

Lancet Infect Dis. 2015 Aug;15(8):905-12. doi: 10.1016/S1473-3099(15)70152-0. Epub 2015 Apr 21.

PMID:
25910637
32.

Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome.

Meya DB, Okurut S, Zziwa G, Rolfes MA, Kelsey M, Cose S, Joloba M, Naluyima P, Palmer BE, Kambugu A, Mayanja-Kizza H, Bohjanen PR, Eller MA, Wahl SM, Boulware DR, Manabe YC, Janoff EN.

J Infect Dis. 2015 May 15;211(10):1597-606. doi: 10.1093/infdis/jiu664. Epub 2014 Dec 9.

33.

HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels.

Eller MA, Opollo MS, Liu M, Redd AD, Eller LA, Kityo C, Kayiwa J, Laeyendecker O, Wawer MJ, Milazzo M, Kiwanuka N, Gray RH, Serwadda D, Sewankambo NK, Quinn TC, Michael NL, Wabwire-Mangen F, Sandberg JK, Robb ML.

J Infect Dis. 2015 May 15;211(10):1574-84. doi: 10.1093/infdis/jiu646. Epub 2014 Nov 17.

34.

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13439-44. doi: 10.1073/pnas.1400446111. Epub 2014 Sep 2.

35.

Impaired natural killer cell responses are associated with loss of the highly activated NKG2A(+)CD57(+)CD56(dim) subset in HIV-1 subtype D infection in Uganda.

Naluyima P, Eller MA, Laeyendecker O, Quinn TC, Serwadda D, Sewankambo NK, Gray RH, Michael NL, Wabwire-Mangen F, Robb ML, Sandberg JK.

AIDS. 2014 Jun 1;28(9):1273-8. doi: 10.1097/QAD.0000000000000286.

36.

Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.

McLinden RJ, Labranche CC, Chenine AL, Polonis VR, Eller MA, Wieczorek L, Ochsenbauer C, Kappes JC, Perfetto S, Montefiori DC, Michael NL, Kim JH.

PLoS One. 2013 Nov 28;8(11):e77756. doi: 10.1371/journal.pone.0077756. eCollection 2013.

37.

Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients.

Beck Z, Jagodzinski LL, Eller MA, Thelian D, Matyas GR, Kunz AN, Alving CR.

PLoS One. 2013 Nov 25;8(11):e81002. doi: 10.1371/journal.pone.0081002. eCollection 2013.

38.

Differential loss of invariant natural killer T cells and FoxP3⁺ regulatory T cells in HIV-1 subtype A and subtype D infections.

Flach B, Naluyima P, Blom K, Gonzalez VD, Eller LA, Laeyendecker O, Quinn TC, Serwadda D, Sewankambo NK, Wawer MJ, Gray RH, Michael NL, Wabwire-Mangen F, Robb ML, Eller MA, Sandberg JK.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):289-93. doi: 10.1097/QAI.0b013e31828b2073.

39.

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection.

Eller MA, Eller LA, Ratto-Kim S, Ouma BJ, Lo V, de Souza M, Guwatudde D, Nails B, Michael NL, Wabwire-Mangen F, Robb ML, Marovich MA, Sandberg JK, Currier JR.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):9-18. doi: 10.1097/QAI.0b013e31825c1217.

PMID:
22580564
40.

OMIP-007: phenotypic analysis of human natural killer cells.

Eller MA, Currier JR.

Cytometry A. 2012 Jun;81(6):447-9. doi: 10.1002/cyto.a.22033. Epub 2012 Mar 12. No abstract available.

41.

Short communication: Colony-forming hematopoietic progenitor cells are not preferentially infected by HIV type 1 subtypes A and D in vivo.

Mullis CE, Oliver AE, Eller LA, Guwatudde D, Mueller AC, Eller MA, Kibuuka H, Robb M, Quinn TC, Redd AD.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1119-23. doi: 10.1089/AID.2011.0179. Epub 2012 Feb 2.

42.

A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, Darden JM, Polonis VR, Vahey MT, Peel S, Robb ML, Michael NL, Marovich MA.

PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16.

43.

B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.

Oballah P, Flach B, Eller LA, Eller MA, Ouma B, de Souza M, Kibuuka HN, Wabwire-Mangen F, Brown BK, Michael NL, Robb ML, Montefiori D, Polonis VR.

PLoS One. 2011;6(8):e22653. doi: 10.1371/journal.pone.0022653. Epub 2011 Aug 23.

44.

Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans.

Eller MA, Blom KG, Gonzalez VD, Eller LA, Naluyima P, Laeyendecker O, Quinn TC, Kiwanuka N, Serwadda D, Sewankambo NK, Tasseneetrithep B, Wawer MJ, Gray RH, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

PLoS One. 2011 Apr 19;6(4):e18779. doi: 10.1371/journal.pone.0018779.

45.

Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motif.

Eller MA, Koehler RN, Kijak GH, Eller LA, Guwatudde D, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

J Virol. 2011 May;85(10):4802-11. doi: 10.1128/JVI.00111-11. Epub 2011 Mar 16.

46.

Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting.

Olemukan RE, Eller LA, Ouma BJ, Etonu B, Erima S, Naluyima P, Kyabaggu D, Cox JH, Sandberg JK, Wabwire-Mangen F, Michael NL, Robb ML, de Souza MS, Eller MA.

Clin Vaccine Immunol. 2010 Jun;17(6):910-8. doi: 10.1128/CVI.00492-09. Epub 2010 Mar 3.

47.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML.

J Infect Dis. 2010 Feb 15;201(4):600-7. doi: 10.1086/650299.

48.

High-throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real-time PCR.

Koehler RN, Walsh AM, Moqueet N, Currier JR, Eller MA, Eller LA, Wabwire-Mangen F, Michael NL, Robb ML, McCutchan FE, Kijak GH.

Tissue Antigens. 2009 Jul;74(1):73-80. doi: 10.1111/j.1399-0039.2009.01265.x.

PMID:
19522772
49.

Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection.

Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, Guwatudde D, McCutchan FE, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):380-9. doi: 10.1097/QAI.0b013e3181aa256e.

PMID:
19487954
50.

Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials.

Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, Tumusiime R, Wandege J, Sanya R, Sateren WB, Wabwire-Mangen F, Kibuuka H, Robb ML, Michael NL, de Souza MS.

PLoS One. 2008;3(12):e3919. doi: 10.1371/journal.pone.0003919. Epub 2008 Dec 11.

Supplemental Content

Loading ...
Support Center